Cardiac Medications and the Renin-Angiotensin-Aldosterone System

Activity Summary

Required reading for all learners: Implicit Bias impacts patient outcomes

This session reviews the management of the renin-angiotensin-aldosterone system (RAAS) in regard to myocardial infarction, heart failure and hypertension. The physiology and pharmacologic management of the RAAS is reviewed. Pharmacology, indications, contraindications, adverse reactions and nursing considerations are presented. Relevant clinical trials for each class of medications are reviewed to illustrate evidence-based utilization.

Objectives

Identify the role of the RAAS in the progression of cardiac disease.
Discuss the indications for medications affecting the RAAS.
Consider the nursing implications for each class of medications that modify the RAAS, including side effects and monitoring parameters.

Continuing Education Disclosure Statement

Criteria for Awarding Contact Hours

Learners must complete the entire activity and the associated evaluation AND read Implicit Bias impacts patient outcomes. No partial credit will be awarded.

Accreditation

American Association of Critical-Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider number CEP 1036, for {contactHours} contact hours.

Disclosures

The Nurse Planner has determined that no individuals with the ability to control content of this activity have relevant relationships with ineligible companies.

Activities with pharmacotherapeutic credit are to assist the APRN in fulfilling their education requirements for licensure and certification renewals.

Refund Policy

Continuing Education Activities are nonrefundable.